Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus

Objective: To evaluate the effect of sitagliptin on somatosensory-evoked potentials (SEPs) and metabolic control in patients with type 2 diabetes mellitus without clinical diabetic neuropathy. Materials and methods: Interventional, prospective, and open study. Patients with less than six months from the diagnosis were included. Examinations of SEPs and laboratory tests at fasting and after food stimulation were performed before and after three months of treatment with sitagliptin (100 mg/day). Results: There was a reduction in the mean levels of HbA1c (P < 0.0001), fasting glucose (P = 0.001), total cholesterol (P = 0.019), and ALT (P = 0.022). An increase in active GLP-1 was found at the end of the study (P = 0.0025). Several SEPs showed statistically significant differences when analyzed before and after treatment with sitagliptin. Conclusion: The results give a glimpse of the possible use of sitagliptin in the treatment of some neurodegenerative conditions of the peripheral nervous system, in addition to its already established role in glycemic control.

Saved in:
Bibliographic Details
Main Authors: Barros,Joelma Ines Tagliapietra, Fechine,Francisco Vagnaldo, Montenegro Júnior,Renan Magalhães, Vale,Otoni Cardoso do, Fernandes,Virgínia Oliveira, Souza,Marcellus Henrique Loiola Ponte de, Cunha,Gilmara Holanda da, Moraes,Manoel Odorico de, d?Alva,Catarina Brasil, Moraes,Maria Elisabete Amaral de
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Endocrinologia e Metabologia 2014
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302014000400369
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0004-27302014000400369
record_format ojs
spelling oai:scielo:S0004-273020140004003692014-06-13Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitusBarros,Joelma Ines TagliapietraFechine,Francisco VagnaldoMontenegro Júnior,Renan MagalhãesVale,Otoni Cardoso doFernandes,Virgínia OliveiraSouza,Marcellus Henrique Loiola Ponte deCunha,Gilmara Holanda daMoraes,Manoel Odorico ded?Alva,Catarina BrasilMoraes,Maria Elisabete Amaral de Diabetes mellitus type 2 dipeptidyl-peptidase IV inhibitors incretins diabetes complications Objective: To evaluate the effect of sitagliptin on somatosensory-evoked potentials (SEPs) and metabolic control in patients with type 2 diabetes mellitus without clinical diabetic neuropathy. Materials and methods: Interventional, prospective, and open study. Patients with less than six months from the diagnosis were included. Examinations of SEPs and laboratory tests at fasting and after food stimulation were performed before and after three months of treatment with sitagliptin (100 mg/day). Results: There was a reduction in the mean levels of HbA1c (P < 0.0001), fasting glucose (P = 0.001), total cholesterol (P = 0.019), and ALT (P = 0.022). An increase in active GLP-1 was found at the end of the study (P = 0.0025). Several SEPs showed statistically significant differences when analyzed before and after treatment with sitagliptin. Conclusion: The results give a glimpse of the possible use of sitagliptin in the treatment of some neurodegenerative conditions of the peripheral nervous system, in addition to its already established role in glycemic control. info:eu-repo/semantics/openAccessSociedade Brasileira de Endocrinologia e MetabologiaArquivos Brasileiros de Endocrinologia &amp; Metabologia v.58 n.4 20142014-06-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302014000400369en10.1590/0004-2730000002914
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Barros,Joelma Ines Tagliapietra
Fechine,Francisco Vagnaldo
Montenegro Júnior,Renan Magalhães
Vale,Otoni Cardoso do
Fernandes,Virgínia Oliveira
Souza,Marcellus Henrique Loiola Ponte de
Cunha,Gilmara Holanda da
Moraes,Manoel Odorico de
d?Alva,Catarina Brasil
Moraes,Maria Elisabete Amaral de
spellingShingle Barros,Joelma Ines Tagliapietra
Fechine,Francisco Vagnaldo
Montenegro Júnior,Renan Magalhães
Vale,Otoni Cardoso do
Fernandes,Virgínia Oliveira
Souza,Marcellus Henrique Loiola Ponte de
Cunha,Gilmara Holanda da
Moraes,Manoel Odorico de
d?Alva,Catarina Brasil
Moraes,Maria Elisabete Amaral de
Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus
author_facet Barros,Joelma Ines Tagliapietra
Fechine,Francisco Vagnaldo
Montenegro Júnior,Renan Magalhães
Vale,Otoni Cardoso do
Fernandes,Virgínia Oliveira
Souza,Marcellus Henrique Loiola Ponte de
Cunha,Gilmara Holanda da
Moraes,Manoel Odorico de
d?Alva,Catarina Brasil
Moraes,Maria Elisabete Amaral de
author_sort Barros,Joelma Ines Tagliapietra
title Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus
title_short Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus
title_full Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus
title_fullStr Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus
title_full_unstemmed Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus
title_sort effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus
description Objective: To evaluate the effect of sitagliptin on somatosensory-evoked potentials (SEPs) and metabolic control in patients with type 2 diabetes mellitus without clinical diabetic neuropathy. Materials and methods: Interventional, prospective, and open study. Patients with less than six months from the diagnosis were included. Examinations of SEPs and laboratory tests at fasting and after food stimulation were performed before and after three months of treatment with sitagliptin (100 mg/day). Results: There was a reduction in the mean levels of HbA1c (P < 0.0001), fasting glucose (P = 0.001), total cholesterol (P = 0.019), and ALT (P = 0.022). An increase in active GLP-1 was found at the end of the study (P = 0.0025). Several SEPs showed statistically significant differences when analyzed before and after treatment with sitagliptin. Conclusion: The results give a glimpse of the possible use of sitagliptin in the treatment of some neurodegenerative conditions of the peripheral nervous system, in addition to its already established role in glycemic control.
publisher Sociedade Brasileira de Endocrinologia e Metabologia
publishDate 2014
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302014000400369
work_keys_str_mv AT barrosjoelmainestagliapietra effectoftreatmentwithsitagliptinonsomatosensoryevokedpotentialsandmetaboliccontrolinpatientswithtype2diabetesmellitus
AT fechinefranciscovagnaldo effectoftreatmentwithsitagliptinonsomatosensoryevokedpotentialsandmetaboliccontrolinpatientswithtype2diabetesmellitus
AT montenegrojuniorrenanmagalhaes effectoftreatmentwithsitagliptinonsomatosensoryevokedpotentialsandmetaboliccontrolinpatientswithtype2diabetesmellitus
AT valeotonicardosodo effectoftreatmentwithsitagliptinonsomatosensoryevokedpotentialsandmetaboliccontrolinpatientswithtype2diabetesmellitus
AT fernandesvirginiaoliveira effectoftreatmentwithsitagliptinonsomatosensoryevokedpotentialsandmetaboliccontrolinpatientswithtype2diabetesmellitus
AT souzamarcellushenriqueloiolapontede effectoftreatmentwithsitagliptinonsomatosensoryevokedpotentialsandmetaboliccontrolinpatientswithtype2diabetesmellitus
AT cunhagilmaraholandada effectoftreatmentwithsitagliptinonsomatosensoryevokedpotentialsandmetaboliccontrolinpatientswithtype2diabetesmellitus
AT moraesmanoelodoricode effectoftreatmentwithsitagliptinonsomatosensoryevokedpotentialsandmetaboliccontrolinpatientswithtype2diabetesmellitus
AT dalvacatarinabrasil effectoftreatmentwithsitagliptinonsomatosensoryevokedpotentialsandmetaboliccontrolinpatientswithtype2diabetesmellitus
AT moraesmariaelisabeteamaralde effectoftreatmentwithsitagliptinonsomatosensoryevokedpotentialsandmetaboliccontrolinpatientswithtype2diabetesmellitus
_version_ 1756372770769338368